Digitalization of data, changes in how patient data is shared, and large amounts of real-life data (RWD) means hospitals and drug developers can generate richer insights into the patient population, improve clinical trial recruitment and develop more effective treatments for chronic diseases. But the challenge of accessing and interpreting this data remains. These are some of the topics of Purplelab-sponsored webinars that eliminate blind spots in the patient journey.
The webinar panel members include Steve Emrick, Senior Vice President, Clinical Information Solutions and Health Contacts, Purplelab; Russ Cobb, Chief Marketing Officer of Purplelab; and Dr. Ben Freiberg, PhD, of the main information systems, led by Genentech’s GCS computing catalyst. Genentech is part of Roche.
The RWD may include data from an electronic medical record, medical claim data, data from a disease registry or connected device.
“When we look at large datasets, we need to consider what questions we need to answer? If you have clarity on this, that can help filter out noise,” Amyk said. “So with any patient journey, like non-small cell lung cancer, when do patients start symptoms? What type of diagnosis is the diagnosis? What type of drug is it a targeted treatment? Is it a targeted treatment relative to non-targeted therapy? Is there a biomarker test that can run, and if not, why can they use this treatment?”
Freiberg observed that the more people out of patient data outside of electronic medical records, the easier it is to detect disease patterns and make new insights based on that information.
The webinar also highlighted:
- The value of obtaining more social determinants (SDOH) data
- Impact of SDOH data in oncology
- Personalized marketing to patients
- Use RWD to change clinical trial recruitment, clinical endpoints and inform market access strategies
Visit the recording of the webinar Eliminate blind spots during the patient's journeyfill in the form below.
picture: Yuoak, Getty Images
